We serve 2-Butyl Octanedioic acid CAS:50905-10-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: 2-Butyl Octanedioic acid
CAS.NO:50905-10-7
Synonyms:
2-butyl-4-octene-1,3-diol
2-Butyl-octan-1,3-diol
2-Butyloctandicarbonsaeure
2-butyloctane-1,8-dioic acid
2-butyl-octane-1,3-diol
2-butyloctane-1,8-dicarboxylic acid
Molecular Formula:C12H24O2
Molecular Weight: 200.31800
Physical and Chemical Properties:
Density:1.064g/cm3
Boiling point: 397.1ºC at 760mmHg
Flash point: 208.1ºC
Refractive index:/
Specification:
Appearance:Colorless liquid
Purity(gc area %):≥95%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Keep away from heat, sparks, and flame. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Corrosives area.
Application:An important raw material and intermediate used in Organic Synthesis,Pharmaceuticals.
Contact us for information like 2-Butyl Octanedioic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-butyloctane-1,8-dicarboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-butyl-4-octene-1,3-diol Use and application,2-butyloctane-1,8-dicarboxylic acid technical grade,usp/ep/jp grade.
Related News: As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.1-(2-chloroethyl)-4-[3-(trifluoromethyl)phenyl]piperazine,dihydrochloride manufacturer As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.2-(Chloromethyl)-4-methylquinazoline supplier Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).1-oxido-2-[(1,3,4-trimethyl-4,5-dihydroimidazol-1-ium-2-yl)sulfanyl]pyridin-1-ium,tetrafluoroborate vendor The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.
